Skip to main content

Usefulness of Age (≥85 Years) and Residual Mitral Regurgitation >1+/4+) for the reduction of Adverse Outcomes in Patients Receiving the MitraClip

doc comp

By Jonathan Scheiner, Research Assistant

Cardiologists at St. Francis Hospital, the Heart Center®, have collaborated on a recent publication (Chen et al. 2019) in the American Journal of Cardiology to determine factors contributing to patient outcomes following MitraClip® treatment for significant mitral valve regurgitation. Mitral valve regurgitation is a condition in which the heart’s mitral valve does not close properly, leading to blood leaking backwards from one heart chamber to another; since MitraClip® is implanted through a catheter, it is best used for patients with severe mitral regurgitation who may not tolerate open-heart surgery. This study, based entirely on patient data from St. Francis Hospital, sampled high-risk patients for open-heart mitral valve surgery (≥8% chance of mortality) and found that MitraClip® therapy was associated with significantly decreased mitral valve backflow and improved heart contraction. Patients who had residual mitral valve backflow after MitraClip® treatment and patients over the age of 85 were found to have increased risks of future heart failure and overall mortality post-treatment. As MitraClip® is an increasingly utilized technology, investigation of predictors of its longer-term outcomes is a key topic in cardiac research.